Lexicon Pharmaceuticals, Inc. - Product Pipeline Review - 2012

Lexicon Pharmaceuticals, Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Lexicon Pharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data on the Lexicon Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Lexicon Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Lexicon Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Lexicon Pharmaceuticals, Inc. - Brief Lexicon Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Lexicon Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Lexicon Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Lexicon Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Lexicon Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Lexicon Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Lexicon Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Lexicon Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Lexicon Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Keyword

Current R&D Portfolio of Lexicon Pharmaceuticals, Inc.; Lexicon Pharmaceuticals, Inc. - Key Therapeutics; Lexicon Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Lexicon Pharmaceuticals, Inc. - News; Lexicon Pharmaceuticals, Inc. - Latest Updates; Lexicon Pharmaceuticals, Inc. - Pipeline; Lexicon Pharmaceuticals, Inc. - Discontinued/Dormant Projects SHOW LESS READ MORE >

List of Tables
List of Figures
Lexicon Pharmaceuticals, Inc. Snapshot
Lexicon Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Lexicon Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Lexicon Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Lexicon Pharmaceuticals, Inc. – Pipeline Products Glance
Lexicon Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Lexicon Pharmaceuticals, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Lexicon Pharmaceuticals, Inc. – Drug Profiles
LX1031
Product Description
Mechanism of Action
R&D Progress
LX1032
Product Description
Mechanism of Action
R&D Progress
LX1033
Product Description
Mechanism of Action
R&D Progress
LX2931
Product Description
Mechanism of Action
R&D Progress
LX4211
Product Description
Mechanism of Action
R&D Progress
LX4211 + Metformin
Product Description
Mechanism of Action
R&D Progress
LX7101
Product Description
Mechanism of Action
R&D Progress
Lexicon Pharmaceuticals, Inc. – Pipeline Analysis
Lexicon Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Lexicon Pharmaceuticals, Inc. – Pipeline Products By Target
Lexicon Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Lexicon Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action
Lexicon Pharmaceuticals, Inc. – Recent Pipeline Updates
Lexicon Pharmaceuticals, Inc. - Dormant Projects
Lexicon Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
LG843
LX6171
Lexicon Pharmaceuticals, Inc. – Company Statement
Lexicon Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Lexicon Pharmaceuticals, Inc., Recent Developments
Lexicon Pharmaceuticals, Inc.- Press Release
Mar 20, 2012: Lexicon's Telotristat Etiprate Receives FDA Orphan Drug Designation For Carcinoid Syndrome Treatment
Jan 09, 2012: Lexicon's LX4211 Enhances Effects Of DPP-4 Inhibition In Patients With Type 2 Diabetes
Nov 26, 2009: Lexicon Presents Positive Top-Line Phase II Results For LX1031 In Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
Nov 13, 2009: Lexicon Announces Positive Phase II Results Of LX1031 In Non-Constipating Irritable Bowel Syndrome
Sep 15, 2009: Exicon Initiates Phase 2 Clinical Trial Of LX4211
Aug 05, 2009: Initiation Of Phase 2 Clinical Trial Of LX2931 For Rheumatoid Arthritis Treatment
Jul 21, 2009: LX1032 Receives Orphan Drug Designation From EMEA For Carcinoid Syndrome
Jul 08, 2009: LX1032 Phase 2 Clinical Trial Initiated By Lexicon In Patients With Carcinoid Syndrome
May 27, 2009: Lexicon To Present Clinical Data For LX1031 At Digestive Disease Week
May 27, 2009: Lexicon To Present Clinical Data For LX1032 At Digestive Disease Week
Mar 06, 2009: Lexicon Presents Clinical Data On LX1032 For Carcinoid Syndrome
Jan 12, 2009: Lexicon Initiates Phase II Clinical Trial Of LX1031 In Patients With Irritable Bowel Syndrome
Financial Deals Landscape
Lexicon Pharmaceuticals, Inc., Deals Summary
Lexicon Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Partnerships
BioSeek Enters Into Research Agreement With Lexicon Pharma
Nuevolution Enters Into Co-Development Agreement With Lexicon Pharma
Lexicon Enters Into Co-Development Agreement With Symphony
Lexicon Extends Collaboration With Bristol-Myers
Takeda Enters Into Co-Development Agreement With Lexicon
Lexicon Expands Collaboration With Genentech
Lexicon Genetics Enters Into Collaboration With Taconic Farms
Lexicon Enters Into Collaboration Agreement With XOMA
Lexicon Enters Into Agreement With Organon
Lexicon Enters Into Collaboration Agreement With Takeda
Licensing Agreements
Lexicon Pharma Enter Into License Agreement With Cellectis
Lexicon Expands Its Licensing Agreement With Stem Cell
Lexicon Enters Into Licensing Agreement With Johnson & Johnson
Lexicon Extends Licensing Agreement With Roche
Equity Offering
Lexicon Pharma Completes Rights Offering Of Common Stock For $161 Million
Lexicon Pharma Completes Underwritten Public Offering Of $111 Million
Lexicon Pharma Completes Private Placement Of $75 Million
Lexicon Pharma Completes Public Offering Of $57 Million
Lexicon Pharma Completes Private Placement Of $205 Million
Lexicon Completes Private Placement Of $40 Million
Lexicon Completes Issue Of $3.67 million
Acquisition
Lexicon Pharma Completes Acquisition Of Symphony Icon
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Lexicon Pharmaceuticals, Inc., Key Information
Lexicon Pharmaceuticals, Inc., Key Facts
Lexicon Pharmaceuticals, Inc. – Pipeline by Indication, 2012
Lexicon Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
Lexicon Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
Lexicon Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012
Lexicon Pharmaceuticals, Inc. – Phase II, 2012
Lexicon Pharmaceuticals, Inc. – Pre-Clinical, 2012
Lexicon Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
Lexicon Pharmaceuticals, Inc. - Pipeline By Target, 2012
Lexicon Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012
Lexicon Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, 2012
Lexicon Pharmaceuticals, Inc. – Recent Pipeline Updates, 2012
Lexicon Pharmaceuticals, Inc. - Dormant Developmental Projects,2012
Lexicon Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2012
Lexicon Pharmaceuticals, Inc., Subsidiaries
Lexicon Pharmaceuticals, Inc., Deals Summary
BioSeek Enters Into Research Agreement With Lexicon Pharma
Nuevolution Enters Into Co-Development Agreement With Lexicon Pharma
Lexicon Enters Into Co-Development Agreement With Symphony
Lexicon Extends Collaboration With Bristol-Myers
Takeda Enters Into Co-Development Agreement With Lexicon
Lexicon Expands Collaboration With Genentech
Lexicon Genetics Enters Into Collaboration With Taconic Farms
Lexicon Enters Into Collaboration Agreement With XOMA
Lexicon Enters Into Agreement With Organon
Lexicon Enters Into Collaboration Agreement With Takeda
Lexicon Pharma Enter Into License Agreement With Cellectis
Lexicon Expands Its Licensing Agreement With Stem Cell
Lexicon Enters Into Licensing Agreement With Johnson & Johnson
Lexicon Extends Licensing Agreement With Roche
Lexicon Pharma Completes Rights Offering Of Common Stock For $161 Million
Lexicon Pharma Completes Underwritten Public Offering Of $111 Million
Lexicon Pharma Completes Private Placement Of $75 Million
Lexicon Pharma Completes Public Offering Of $57 Million
Lexicon Pharma Completes Private Placement Of $205 Million
Lexicon Completes Private Placement Of $40 Million
Lexicon Completes Issue Of $3.67 million
Lexicon Pharma Completes Acquisition Of Symphony Icon

List of Figures
Lexicon Pharmaceuticals, Inc. – Pipeline by Indication, 2012
Lexicon Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
Lexicon Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
Lexicon Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012
Lexicon Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
Lexicon Pharmaceuticals, Inc. - Pipeline By Target, 2012
Lexicon Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012